Pricing Log in Create free account

Roivant Sciences Ltd. (ROIV) vs Revolution Medicines, Inc. (RVMD)

Roivant Sciences Ltd. and Revolution Medicines, Inc. are both Biotechnology companies. Revolution Medicines, Inc. is the larger, with a market value of $38.1B against $26.5B — 1.4× the size. Revolution Medicines, Inc. grew revenue faster over the last twelve months: 491.1% against −67.6%. Revolution Medicines, Inc. has the higher net margin (−894.4% vs −3,535.0%) and the higher return on invested capital (0.00% vs −34.5%). Across the 17 metrics below, Revolution Medicines, Inc. leads on 11 and Roivant Sciences Ltd. on 6.

Valuation

Metric ROIV RVMD Biotechnology median
P/E n/m n/m 10.26
P/S 3,528.29 184.79 9.18
P/B 5.40 16.09 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 3,061.16 172.29 8.98
Earnings yield (1.03%) (5.07%) (34.89%)
Free cash flow yield (3.09%) (3.73%) (24.52%)

Profitability

Metric ROIV RVMD Biotechnology median
Gross margin 81.21% 95.62% 65.16%
Operating margin (7,914.75%) (805.75%) 0.00%
Net margin (3,534.96%) (894.40%) 0.00%
Free cash flow margin (10,901.00%) (688.93%) 0.00%
Return on equity (5.47%) (93.56%) (50.12%)
Return on assets (5.15%) (57.07%) (45.60%)
Return on invested capital (34.51%) 0.00% 0.00%

Growth

Metric ROIV RVMD Biotechnology median
Revenue growth (TTM) (67.58%) 491.12% 6.26%
EPS growth (last fiscal year) (125.00%) (66.20%) 29.88%
Revenue growth, 5-year CAGR (19.07%) (10.50%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ROIV RVMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.72 8.36 4.89
Net debt to EBITDA 8.39 1.47 1.01

Dividend

Metric ROIV RVMD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ROIV RVMD Biotechnology median
Market cap 26.45b 38.08b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack